#KO
### ğŸ’Š ì•ŒëŸ¬í…ì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - íš¨ëŠ¥ ë° íš¨ê³¼
* ì´ ì•½ì€ ê³„ì ˆì„± ë° ë‹¤ë…„ì„± ì•Œë ˆë¥´ê¸°ì„± ë¹„ì—¼, ì•Œë ˆë¥´ê¸°ì„± ê²°ë§‰ì—¼, ë§Œì„± íŠ¹ë°œì„± ë‘ë“œëŸ¬ê¸°, í”¼ë¶€ê°€ë ¤ì›€ì¦ê³¼Â í•˜ì´ë“œë¡œì½”í‹°ì† ì™¸ìš©ì œì™€ ë³‘ìš©ì— ì˜í•œ ìŠµì§„, í”¼ë¶€ì—¼ì— ì‚¬ìš©í•©ë‹ˆë‹¤.

### ğŸ•’ ì•ŒëŸ¬í…ì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - ìš©ë²• ë° ìš©ëŸ‰
* ë§Œ 6ì„¸ ì´ìƒ ë° ì„±ì¸ì€Â 1íšŒ 1ì •(10 mg)ì”©, 1ì¼ 1íšŒ ì·¨ì¹¨ ì „ì— ë³µìš©í•©ë‹ˆë‹¤.

ì´ìƒë°˜ì‘ì— ë¯¼ê°í•œ í™˜ìì˜ ê²½ìš°, Â½ì •(5 mg)ì”©, ì•„ì¹¨, ì €ë…ì— ë¶„í• í•˜ì—¬ ë³µìš©í•©ë‹ˆë‹¤.

ì—°ë ¹, ì¦ìƒì— ë”°ë¼ ì ì ˆíˆ ì¦ê°í•©ë‹ˆë‹¤.

ì‹ ì¥ì•  í™˜ìì˜ íˆ¬ì—¬ ê°„ê²©ì€ í™˜ìì˜ ì‹ ê¸°ëŠ¥ì— ë”°ë¼ ì¡°ì ˆë˜ì–´ì•¼ í•˜ê³ , ì‹ ì¥ì• ë¥¼ ê°€ì§„ ì†Œì•„ í™˜ìëŠ” í™˜ìì˜ ì‹  ì²­ì†Œìœ¨ê³¼ ì²´ì¤‘ì„ ê³ ë ¤í•˜ì—¬ ê°œë³„ì ìœ¼ë¡œ ìš©ëŸ‰ì„ ì¡°ì ˆí•´ì•¼ í•˜ë¯€ë¡œ ìì„¸í•œ ì‚¬í•­ì€ í—ˆê°€ì‚¬í•­ì„ ì°¸ê³ í•˜ì‹­ì‹œì˜¤.

### âš ï¸ ì•ŒëŸ¬í…ì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - ì£¼ì˜ì‚¬í•­
* ì •ë³´ ì—†ìŒ
* ì´ ì•½ ë°Â íˆë“œë¡ì‹œì§„ ë˜ëŠ” í”¼í˜ë¼ì§„ ìœ ë„ì²´ì— ê³¼ë¯¼ì¦ í™˜ì, ì‹ ë¶€ì „ í™˜ì(í¬ë ˆì•„í‹°ë‹Œ ì²­ì†Œìœ¨ 

ì´ ì•½ì„ ë³µìš©í•˜ê¸° ì „ì— ì„ë¶€, ìˆ˜ìœ ë¶€, ì‹ ì¥ì• (ì‹ ì¥ì¥ì• ), ê°„ì¥ì•  í™˜ì, ë…¸ì¸, ë‡Œì „ì¦Â ë° ë°œì‘ ìœ„í—˜ì„±ì´ ìˆëŠ” í™˜ì,Â ì†Œë³€ê³ ì„ì˜ ì„ í–‰ìš”ì¸(ì˜ˆ: ì²™ìˆ˜ ë³‘ë³€, ì „ë¦½ì„  ë¹„ëŒ€ì¦)ì´ ìˆëŠ” í™˜ìëŠ” ì˜ì‚¬ ë˜ëŠ” ì•½ì‚¬ì™€ ìƒì˜í•˜ì‹­ì‹œì˜¤.

ì´ ì•½ì€ ëª¨ìœ ë¥¼ í†µí•´ ë¯¸ëŸ‰ ë¶„ë¹„ë˜ë¯€ë¡œ íˆ¬ì—¬ ì¤‘ì—ëŠ” ìˆ˜ìœ ë¥¼ ì¤‘ë‹¨í•˜ì‹­ì‹œì˜¤.

ì´ ì•½ì€ ì•Œë ˆë¥´ê¸°í•­ì›í”¼ë‚´ë°˜ì‘ì„ ì–µì œí•˜ë¯€ë¡œ ì•Œë ˆë¥´ê¸°í•­ì›í”¼ë‚´ë°˜ì‘ê²€ì‚¬ ì‹¤ì‹œ 3~5ì¼ ì „ì—ëŠ” ì´ ì•½ì„ íˆ¬ì—¬í•˜ì§€ ì•ŠëŠ” ê²ƒì´ ë°”ëŒì§í•©ë‹ˆë‹¤.

# EN
### ğŸ’Š ì•ŒëŸ¬í…ì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - Efficacy and Effects
* This medication is used for seasonal and perennial allergic rhinitis, allergic conjunctivitis, chronic idiopathic urticaria, pruritus, and in combination with hydrocortisone topical preparations for eczema and dermatitis.

### ğŸ•’ ì•ŒëŸ¬í…ì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - Dosage and Administration
* **For adults and children aged 6 years and older:** Take 1 tablet (10 mg) once daily, at bedtime.
* **For patients sensitive to adverse reactions:** Take Â½ tablet (5 mg) twice daily, in the morning and evening, in divided doses.
* The dosage may be adjusted appropriately depending on age and symptoms.
* For patients with renal impairment, the dosing interval should be adjusted according to the patient's renal function. For pediatric patients with renal impairment, the dosage should be individually adjusted considering the patient's renal clearance and body weight. Please refer to the prescribing information for detailed instructions.

### âš ï¸ ì•ŒëŸ¬í…ì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - Precautions
* This drug is contraindicated in patients with hypersensitivity to this drug, hydroxyzine, or piperazine derivatives, and in patients with severe renal failure (creatinine clearance <10 mL/min).
* Before taking this medication, consult a doctor or pharmacist if you are pregnant, breastfeeding, have renal impairment (kidney disorder), hepatic impairment, are elderly, have epilepsy or a risk of seizures, or have predisposing factors for urinary retention (e.g., spinal cord lesion, prostatic hypertrophy).
* This medication is secreted in small amounts into breast milk, so discontinue breastfeeding during treatment.
* This medication inhibits allergen skin prick tests, so it is advisable not to administer it 3 to 5 days before conducting an allergen skin prick test.

---

# CN
### ğŸ’Š ì•ŒëŸ¬í…ì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - åŠŸæ•ˆä¸ä½œç”¨
* æœ¬è¯ç”¨äºå­£èŠ‚æ€§å’Œå¸¸å¹´æ€§è¿‡æ•æ€§é¼»ç‚ã€è¿‡æ•æ€§ç»“è†œç‚ã€æ…¢æ€§ç‰¹å‘æ€§è¨éº»ç–¹ã€çš®è‚¤ç˜™ç—’ç—‡ï¼Œä»¥åŠä¸æ°¢åŒ–å¯çš„æ¾å¤–ç”¨åˆ¶å‰‚è”åˆç”¨äºæ¹¿ç–¹ã€çš®ç‚ã€‚

### ğŸ•’ ì•ŒëŸ¬í…ì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - ç”¨æ³•ç”¨é‡
* **6å²ä»¥ä¸Šå„¿ç«¥åŠæˆäººï¼š** æ¯æ¬¡1ç‰‡ï¼ˆ10æ¯«å…‹ï¼‰ï¼Œæ¯æ—¥ä¸€æ¬¡ï¼Œç¡å‰æœç”¨ã€‚
* **å¯¹ä¸è‰¯ååº”æ•æ„Ÿçš„æ‚£è€…ï¼š** æ¯æ¬¡Â½ç‰‡ï¼ˆ5æ¯«å…‹ï¼‰ï¼Œæ—©æ™šåˆ†æ¬¡æœç”¨ã€‚
* å‰‚é‡å¯æ ¹æ®å¹´é¾„å’Œç—‡çŠ¶é€‚å½“å¢å‡ã€‚
* è‚¾åŠŸèƒ½ä¸å…¨æ‚£è€…çš„ç»™è¯é—´éš”åº”æ ¹æ®æ‚£è€…çš„è‚¾åŠŸèƒ½è¿›è¡Œè°ƒæ•´ï¼›æ‚£æœ‰è‚¾åŠŸèƒ½ä¸å…¨çš„å„¿ç«¥æ‚£è€…ï¼Œåº”æ ¹æ®æ‚£è€…çš„è‚¾æ¸…é™¤ç‡å’Œä½“é‡å•ç‹¬è°ƒæ•´å‰‚é‡ï¼Œè¯¦ç»†ä¿¡æ¯è¯·å‚è€ƒè¯å“è¯´æ˜ä¹¦ã€‚

### âš ï¸ ì•ŒëŸ¬í…ì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - æ³¨æ„äº‹é¡¹
* æœ¬è¯åŠç¾Ÿå—ªæˆ–å“Œå—ªè¡ç”Ÿç‰©è¿‡æ•è€…ã€é‡åº¦è‚¾åŠŸèƒ½ä¸å…¨æ‚£è€…ï¼ˆè‚Œé…æ¸…é™¤ç‡ï¼œ10 mL/minï¼‰ç¦ç”¨ã€‚
* æœç”¨æœ¬è¯å‰ï¼Œå­•å¦‡ã€å“ºä¹³æœŸå¦‡å¥³ã€è‚¾åŠŸèƒ½ä¸å…¨ï¼ˆè‚¾è„éšœç¢ï¼‰ã€è‚åŠŸèƒ½ä¸å…¨æ‚£è€…ã€è€å¹´äººã€ç™«ç—«å’Œæœ‰ç™«ç—«å‘ä½œé£é™©çš„æ‚£è€…ã€æœ‰å°¿æ½´ç•™è¯±å‘å› ç´ ï¼ˆå¦‚è„Šé«“ç—…å˜ã€å‰åˆ—è…ºè‚¥å¤§ï¼‰çš„æ‚£è€…ï¼Œè¯·å’¨è¯¢åŒ»ç”Ÿæˆ–è¯å¸ˆã€‚
* æœ¬è¯ä¼šå¾®é‡åˆ†æ³Œåˆ°æ¯ä¹³ä¸­ï¼Œå› æ­¤æœç”¨æœŸé—´è¯·åœæ­¢å“ºä¹³ã€‚
* æœ¬è¯ä¼šæŠ‘åˆ¶è¿‡æ•åŸçš®å†…ååº”ï¼Œå› æ­¤å»ºè®®åœ¨è¿›è¡Œè¿‡æ•åŸçš®å†…ååº”æµ‹è¯•å‰3~5å¤©åœæ­¢æœç”¨æœ¬è¯ã€‚

---

# JP
### ğŸ’Š ì•ŒëŸ¬í…ì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - åŠ¹èƒ½ãƒ»åŠ¹æœ
* ã“ã®è–¬å‰¤ã¯ã€å­£ç¯€æ€§ãŠã‚ˆã³é€šå¹´æ€§ã‚¢ãƒ¬ãƒ«ã‚®ãƒ¼æ€§é¼»ç‚ã€ã‚¢ãƒ¬ãƒ«ã‚®ãƒ¼æ€§çµè†œç‚ã€æ…¢æ€§ç‰¹ç™ºæ€§è•éº»ç–¹ã€çš®è†šãã†ç—’ç—‡ã€ãŠã‚ˆã³ãƒ’ãƒ‰ãƒ­ã‚³ãƒ«ãƒã‚¾ãƒ³å¤–ç”¨å‰¤ã¨ã®ä½µç”¨ã«ã‚ˆã‚‹æ¹¿ç–¹ã€çš®è†šç‚ã«ä½¿ç”¨ã•ã‚Œã¾ã™ã€‚

### ğŸ•’ ì•ŒëŸ¬í…ì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - ç”¨æ³•ãƒ»ç”¨é‡
* **6æ­³ä»¥ä¸ŠãŠã‚ˆã³æˆäººï¼š** 1å›1éŒ ï¼ˆ10 mgï¼‰ã‚’1æ—¥1å›ã€å°±å¯å‰ã«æœç”¨ã—ã¾ã™ã€‚
* **å‰¯ä½œç”¨ã«æ•æ„Ÿãªæ‚£è€…ã®å ´åˆï¼š** 1å›Â½éŒ ï¼ˆ5 mgï¼‰ã‚’æœã¨å¤•ã«åˆ†ã‘ã¦æœç”¨ã—ã¾ã™ã€‚
* å¹´é½¢ã€ç—‡çŠ¶ã«å¿œã˜ã¦é©åˆ‡ã«å¢—æ¸›ã—ã¾ã™ã€‚
* è…æ©Ÿèƒ½éšœå®³æ‚£è€…ã®æŠ•ä¸é–“éš”ã¯ã€æ‚£è€…ã®è…æ©Ÿèƒ½ã«å¿œã˜ã¦èª¿æ•´ã•ã‚Œã‚‹ã¹ãã§ã‚ã‚Šã€è…æ©Ÿèƒ½éšœå®³ã‚’æŒã¤å°å…æ‚£è€…ã¯ã€æ‚£è€…ã®è…ã‚¯ãƒªã‚¢ãƒ©ãƒ³ã‚¹ã¨ä½“é‡ã‚’è€ƒæ…®ã—ã¦å€‹åˆ¥ã«ç”¨é‡ã‚’èª¿æ•´ã™ã‚‹å¿…è¦ãŒã‚ã‚‹ãŸã‚ã€è©³ç´°ã«ã¤ã„ã¦ã¯æ·»ä»˜æ–‡æ›¸ã‚’å‚ç…§ã—ã¦ãã ã•ã„ã€‚

### âš ï¸ ì•ŒëŸ¬í…ì •(ì„¸í‹°ë¦¬ì§„ì—¼ì‚°ì—¼) - æ³¨æ„äº‹é …
* æœ¬å‰¤ãŠã‚ˆã³ãƒ’ãƒ‰ãƒ­ã‚­ã‚·ã‚¸ãƒ³ã¾ãŸã¯ãƒ”ãƒšãƒ©ã‚¸ãƒ³èª˜å°ä½“ã«å¯¾ã—éæ•ç—‡ã®æ‚£è€…ã€é‡åº¦ã®è…ä¸å…¨æ‚£è€…ï¼ˆã‚¯ãƒ¬ã‚¢ãƒãƒ‹ãƒ³ã‚¯ãƒªã‚¢ãƒ©ãƒ³ã‚¹ãŒ10 mL/minæœªæº€ï¼‰ã«ã¯æŠ•ä¸ã—ãªã„ã§ãã ã•ã„ã€‚
* æœ¬å‰¤ã‚’æœç”¨ã™ã‚‹å‰ã«ã€å¦Šå©¦ã€æˆä¹³å©¦ã€è…æ©Ÿèƒ½éšœå®³ï¼ˆè…è‡“éšœå®³ï¼‰ã€è‚æ©Ÿèƒ½éšœå®³æ‚£è€…ã€é«˜é½¢è€…ã€ã¦ã‚“ã‹ã‚“ãŠã‚ˆã³ç™ºä½œã®ãƒªã‚¹ã‚¯ãŒã‚ã‚‹æ‚£è€…ã€å°¿é–‰ã®å…ˆè¡Œè¦å› ï¼ˆä¾‹ï¼šè„Šé«„ç—…å¤‰ã€å‰ç«‹è…ºè‚¥å¤§ç—‡ï¼‰ãŒã‚ã‚‹æ‚£è€…ã¯ã€åŒ»å¸«ã¾ãŸã¯è–¬å‰¤å¸«ã«ã”ç›¸è«‡ãã ã•ã„ã€‚
* æœ¬å‰¤ã¯æ¯ä¹³ä¸­ã«å¾®é‡åˆ†æ³Œã•ã‚Œã‚‹ãŸã‚ã€æŠ•ä¸ä¸­ã¯æˆä¹³ã‚’ä¸­æ­¢ã—ã¦ãã ã•ã„ã€‚
* æœ¬å‰¤ã¯ã‚¢ãƒ¬ãƒ«ã‚®ãƒ¼æŠ—åŸçš®å†…åå¿œã‚’æŠ‘åˆ¶ã™ã‚‹ãŸã‚ã€ã‚¢ãƒ¬ãƒ«ã‚®ãƒ¼æŠ—åŸçš®å†…åå¿œæ¤œæŸ»å®Ÿæ–½ã®3ï½5æ—¥å‰ã«ã¯æœ¬å‰¤ã‚’æŠ•ä¸ã—ãªã„ã“ã¨ãŒæœ›ã¾ã—ã„ã§ã™ã€‚